Vical Incorporated (NASDAQ:VICL), a biopharmaceutical company, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. Vical Incorporated (NASDAQ:VICL) weekly performance is 0.84%. On last trading day company shares ended up $1.20. Analysts mean target price for the company is $3.23. Vical Incorporated (NASDAQ:VICL) distance from 50-day simple moving average (SMA50) is -2.94%.
Johnson & Johnson (NYSE:JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) immunotherapy platform. Johnson & Johnson (NYSE:JNJ) shares advanced 0.69% in last trading session and ended the day on $101.46. JNJ Gross Margin is 69.10% and its return on assets is 11.60%. Johnson & Johnson (NYSE:JNJ) quarterly performance is 10.91%.
The French CEO of UK drugmaker AstraZeneca plc (ADR) (NYSE:AZN) has spent much of the past month surrounded by bankers and lawyers as he fought off an unwanted approach from Pfizer. High quality global journalism requires investment. With the US drugmaker repelled, at least for now, Mr Soriot is relieved to be getting back to the business of making medicines: “I find it a lot more exciting to be talking to customers and scientists.” AstraZeneca plc (ADR) (NYSE:AZN) shares moved up 1.28% in last trading session and was closed at $72.20, while trading in range of $71.60 – $72.50. AstraZeneca plc (ADR) (NYSE:AZN) year to date (YTD) performance is 25.11%.
Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended the last trading day at $50.49. Company weekly volatility is calculated as 2.03% and price to cash ratio as 52.85. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) showed a negative weekly performance of -0.34%.
ASTELLAS PHARMA INC (OTCMKTS:ALPMY)’s androgen receptor signaling inhibitor, XTANDI® is now available for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas and Medivation are collaborating on a comprehensive development program that includes studies to develop enzalutamide across the full spectrum of advanced prostate cancer as well as advanced breast cancer. ASTELLAS PHARMA INC (OTCMKTS:ALPMY) on last trading day company shares ended up $12.87.